Clinical study of high-dose ambroxol for treatment of acute exacerbations in chronic obstructive pulmonary disease

VernacularTitle:大剂量沐舒坦治疗慢性阻塞性肺病急性加重期的临床研究
Author: Yong LI ; Feng WU ; Tingyan LIN
Publication Type:Journal Article
Keywords: Ambroxol; AECOPD; Intravenous infusion
From: Chinese Journal of Geriatrics 2013;(2):162-164
CountryChina
Language:Chinese
Abstract: Objective To evaluate the efficacy and safety of high-dose ambroxol in treating acute exacerbations in chronic obstructive pulmonary disease (AECOPD).Methods The trial design was random,open,and parallel control.126 patients with AECOPD were involved.High-dose group received ambroxol 150 mg 3 times per day for 7 days (n=46),while conventional-dose group given ambroxol 30 mg 3 times per day for 7 days (n=40) and control group was given a routine treatment (antibiotic therapy,oxygen inhalation and bronchodilators) (n=40).Results The effective rates of high-dose group and conventional-dose group (95.6 ％,77.5 ％) were significantly higher compared with control group (55.0％) (x2 =19.81,4.53,both P＜0.05).The average duration of hospitalization was significantly lower in high-dose group (10.78 ±0.95)d and conventional-dose group (11.75±0.84)d comparing with control group (13.15±0.89)d (q=11.88,7.24,both P＜0.05).The clinical efficacy in high dose group was much better.Conclusions High-dose ambroxol is a safe and efficient therapy in the treatment of acute exacerbations in chronic obstructive pulmonary disease.